Based on clinical trials, with the use of GLP-1 medications and lifestyle adjustments, patients can anticipate losing 10% to 18% of their body weight, based on the average weight loss in three 68-week clinical trials
This means that body fat percentage affects distribution volume less than total body weight
Prescription oral options exist too, formulated specifically to survive digestion, again with standardized dosing
Our FDA-approved labels include robust warnings, including that Mounjaro and Zepbound may be associated with gastrointestinal adverse reactions, sometimes severe. Game changer for obesity medicine Its now estimated that more than 15 million Americans use GLP-1 medications
A good rule of thumb is to choose a new spot for each injection, staying at least two inches away from your last one
tightness in the chest or throat